Summary:
Imatinib, or Glivec (Gleevec-USA), is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance.

The study findings strengthen the hypothesis that domestic use of pesticides may play a role in the etiology of childhood hematopoietic malignancies. The consistency of the findings with those of previous studies on AL raises the question of the advisability of preventing pesticide use by pregnant women.

ChemGenex Investigators Report Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients with the T315I Mutation

....more

Bosutinib: A New Kinase Inhibitor for Treatment of Philadelphia Chromosome Positive Leukemia

Researchers involved in an international study have reported that bosutinib (SKI606) is a new active kinase inhibitor for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphoid leukemia (ALL). The details of this study were presented at the 2007 meeting of the American Society of Clinical Oncology in June.

December 10th 2007


PORTLAND, Ore. - Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).

Report on the 6th CML Patient and Carer Seminar held in Edinburgh on Saturday 24th November 2007

The seminar was held at Houstoun House Hotel which is just outside of Edinburgh and was hosted by Tessa Holyoake from Glasgow in collaboration with Steve O'Brien from Newcastle.

Please use this template as a basis (you can change it if you need to) for contacting your MP and making them aware of the situation regarding the proposed NICE appraisal for both Dasatinib and Nilotinib. It is crucial that as many people as possible help put pressure on the Health Dept. to go ahead with an appraisal for both of these drugs as it will ensure NHS funding and therefore access to alternative life saving therapy for Glivec resistant CML patients.

NCCN 2nd Annual Congress: Hematologic Malignancies - Update on Primary Therapy, Second-Line Therapy, and New Agents for Chronic Myelogenous Leukemia (Slides with Audio) CME/CE
Jerald P. Radich, MD

Please click on the link below to download a list of the centres that are open and recruiting.

On 20 September 2007 the CHMP
(Committee for Medicinal Products for Human Use)
of the EMEA
(European Medicines Evaluation Agency) adopted a positive opinion towards Tasigna and recommended to grant a marketing authorisation for the drug at 200 mg, hard capsule for CML with intolerance or resistance against Gleevec.